Arcutis Biotherapeutics Receives Analyst Ratings

Summary

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) has received a ‘Moderate Buy’ consensus rating from six analysts, with an average one-year target price of $18.80. One analyst rated it as ‘Hold,’ while five rated it as ‘Buy.’ Recent reports include HC Wainwright’s $19.00 target price and Goldman Sachs raising its target price to $15.00. Insider trading shows Larry Todd Edwards sold 7,451 shares, and Patrick J. Heron purchased 1,890 shares. The stock opened at $13.43, with a 52-week range of $7.64 to $17.75, and a market cap of $1.6 billion.Market Beat

Impact Analysis

This event is at the company level, focusing on Arcutis Biotherapeutics and the analyst ratings it received. The FDA recently approved Arcutis’s Zoryve® topical foam for treating plaque psoriasis, which is a positive catalyst for the company, enhancing its product portfolio and market potential.Reuters The ‘Moderate Buy’ consensus, with upgrades in target prices from notable firms like Goldman Sachs and HC Wainwright, reflects optimism in the company’s growth prospects and potential market performance.Market Beat However, insider trading activities, such as recent stock disposals by officials, might indicate mixed sentiments within the company.Reuters+ 2 The improving price performance and the upgrade in its IBD relative strength rating suggest a strengthening market position.MSN Investment opportunities could include buying ARQT stock in anticipation of continued positive performance following FDA approval and analyst endorsements. However, investors should also consider the company’s negative net profit margin and return on equity, which indicate ongoing financial challenges.Market Beat